Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coya Therapeutics (COYA) Retained Earnings (2022 - 2025)

Coya Therapeutics' Retained Earnings history spans 4 years, with the latest figure at -$56.3 million for Q3 2025.

  • For Q3 2025, Retained Earnings fell 48.82% year-over-year to -$56.3 million; the TTM value through Sep 2025 reached -$56.3 million, down 48.82%, while the annual FY2024 figure was -$40.7 million, 57.55% down from the prior year.
  • Retained Earnings for Q3 2025 was -$56.3 million at Coya Therapeutics, down from -$54.1 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$17.9 million in Q4 2022 and bottomed at -$56.3 million in Q3 2025.
  • The 4-year median for Retained Earnings is -$32.4 million (2024), against an average of -$34.7 million.
  • The largest annual shift saw Retained Earnings tumbled 39.37% in 2024 before it crashed 60.06% in 2025.
  • A 4-year view of Retained Earnings shows it stood at -$17.9 million in 2022, then crashed by 44.7% to -$25.9 million in 2023, then plummeted by 57.55% to -$40.7 million in 2024, then tumbled by 38.09% to -$56.3 million in 2025.
  • Per Business Quant, the three most recent readings for COYA's Retained Earnings are -$56.3 million (Q3 2025), -$54.1 million (Q2 2025), and -$48.0 million (Q1 2025).